Finexsi issued its report as an independent expert in connection with the proposed public buy-out offer followed by a squeeze-out (OPR-RO) initiated by Calliditas Therapeutics AB for the shares of Genkyotex S.A

Following off-market block purchases, a simplified tender offer and the subscription to a capital increase, CALLIDITAS THERAPEUTICS AB held 90.3% of the shares of GENKYOTEX SA, a biopharmaceutical company specialised in the development of NOX therapies. CALLIDITAS THERAPEUTICS AB therefore announced on July 28, 2021 its intention to launch a public withdrawal offer followed by a squeeze-out offer (« OPR-RO ») on the shares of GENKYOTEX SA.

On the recommendation of the Ad Hoc Committee, the Board of Directors appointed on July 2, 2021 Finexsi as an independent expert to issue a report including a fairness opinion on the financial terms and conditions of the transaction. This fairness opinion was attached on July 8, 2021 to the note prepared in response to the public offer.

The assignment was led by Olivier Courau, assisted by Maxime Rogeon.